Methods and compositions for treating herpes infections
A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.
1 - 5 . (canceled)
6 . A pharmaceutical composition for topical administration in the treatment or prophylaxis of herpetic disease in mammals, comprising,
a) an effective amount of immunoglobulin G (IgG) prepared from pooled human plasma;
b) at least one pharmaceutically acceptable excipient appropriate for use in topical formulations.
7 . The pharmaceutical composition of claim 6 , further comprising at least one material that enhances absorption through the skin or other affected area.
8 . The pharmaceutical composition of claim 6 , wherein the effective amount of IgG is from about 0.05% to about 35%, by weight, of the composition.
9 . The pharmaceutical composition of claim 6 , wherein the effective amount of IgG is from about 3% to about 16%, by weight, of the composition.
10 . The pharmaceutical composition of claim 6 , wherein the composition is prepared as a formulation selected from the group consisting of an paraffinic-base ointment, a water-miscible-base ointment, an oil-in-water base cream, and gels.
11 . The pharmaceutical composition of claim 6 , wherein the composition is prepared as a formulation suited for ophthalmic use.
12 . The pharmaceutical composition of claim 11 , wherein the effective amount of IgG is dissolved or suspended in an aqueous solvent.
13 . The pharmaceutical composition of claim 11 , wherein the formulation is adapted for prolonged delivery of IgG or for use during sleep.
14 . The pharmaceutical composition of claim 6 , wherein the composition is prepared as a formulation suited for application to the buccal mucosa.
15 . The pharmaceutical composition of claim 14 , wherein the formulation is a lozenge.
16 . The pharmaceutical composition of claim 6 , wherein the composition is prepared as a formulation suited for vaginal use.
17 . The pharmaceutical composition of claim 16 , wherein the formulation is a dosage form suitable for vaginal insertion.
18 . The pharmaceutical composition of claim 17 , wherein the dosage form is a suppository, gel, or tablet.
19 . The pharmaceutical composition of claim 6 , wherein the pooled human plasma is obtained from donors that are not screened based on their HSV-neutralizing antibody level.
20 . A method of treatment or prophylaxis of herpetic disease in mammals, the method comprising,
administering topically to a mammal an effective amount of a composition comprising immunoglobulin G (IgG) prepared from pooled human plasma.
21 . The method of claim 20 , wherein the herpetic disease is selected from the group consisting of chickenpox, shingles, zoster oticus, zoster varicellosus, keratitis, herpes digitalis, herpes facialis, herpes genitalis, herpes gladiatorum, and herpes stomatitis.
22 . The method of claim 20 , wherein the herpetic disease is female herpes genitales.
23 . The method of claim 20 , wherein the pooled human plasma is obtained from donors that are not screened based on their HSV-neutralizing antibody level.
24 . A method of treatment or prophylaxis of ocular herpetic disease in mammals, the method comprising,
administering topically to a mammal an effective amount of a composition comprising immunoglobulin G (IgG) prepared from pooled human plasma.
25 . The method of claim 24 , wherein the herpetic disease is keratitis.
26 . The method of claim 24 , wherein the composition is a suspension administered directly to an infected eye of a mammal.
27 . The method of claim 24 , wherein the pooled human plasmin is obtained from donors that are not screened based on their HSV-neutralizing antibody level.